menu
    • menu

    Company profile for Akebia Therapeutics

    NEW Drugs in Dev: 4
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We were founded in 2007 to discover and develop therapeutic solutions leveraging the potential of hypoxia inducible factor—or HIF—biology. We believe HIF-Prolyl Hydroxylase (HIF-PH) inhibition could represent an approach to treating certain conditions where there is unmet need. Our objective is to develop and commercialize these products, starting with our lead compound, vadadustat, an investigational product being studied...
    We were founded in 2007 to discover and develop therapeutic solutions leveraging the potential of hypoxia inducible factor—or HIF—biology. We believe HIF-Prolyl Hydroxylase (HIF-PH) inhibition could represent an approach to treating certain conditions where there is unmet need. Our objective is to develop and commercialize these products, starting with our lead compound, vadadustat, an investigational product being studied in patients with anemia due to chronic kidney disease (CKD).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Akebia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    245 First Street, Suite 1400 Cambridge, MA 02142
    Telephone
    Telephone
    +1 617-871-2098
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://akebia.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/akebia-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/akebiatx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    IMCAS World Congress

    IMCAS World Congress

    Not Confirmed

    envelop Contact Supplier

    IMCAS World Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Akebia Pharma Reveals Corporate Updates And 2026 Pipeline
    Akebia Pharma Reveals Corporate Updates And 2026 Pipeline

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216827/37519/en/Akebia-Therapeutics-Announces-Corporate-Updates-and-2026-Pipeline-Outlook.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Akebia Doses First Patient in Phase 2 FSGS Trial of Praliciguat
    Akebia Doses First Patient in Phase 2 FSGS Trial of Praliciguat

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213549/37519/en/Akebia-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Praliciguat-for-the-Treatment-of-Focal-Segmental-Glomerulosclerosis-FSGS.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Rules
    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Rules

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3213185/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Akebia Therapeutics Awards Inducements Under Nasdaq Listing Rule
    Akebia Therapeutics Awards Inducements Under Nasdaq Listing Rule

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3197426/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Akebia Announces Establishment Of Rare Kidney Disease Pipeline
    Akebia Announces Establishment Of Rare Kidney Disease Pipeline

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Akebia to Present at 37th Piper Sandler Healthcare Conference
    Akebia to Present at 37th Piper Sandler Healthcare Conference

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193434/37519/en/Akebia-Therapeutics-to-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search